Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENOLDOPAM MESYLATE vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
In-hospital, short-term (up to 48 hours) management of severe hypertension (hypertensive crisis) when rapid, but quickly reversible, blood pressure reduction is required,Off-label: Management of hypertensive emergencies with acute renal impairment
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
250 mg orally twice daily
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Primarily hepatic via conjugation (glucuronidation and sulfation); CYP450 minimally involved.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Approximately 90% bound to plasma proteins, primarily albumin.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
0.6–0.8 L/kg; moderate distribution consistent with limited tissue penetration.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Intravenous: 100%; no oral bioavailability due to extensive first-pass metabolism (not administered orally).
70-90% (oral); 100% (IV).
No dose adjustment required for renal impairment; however, monitor for hypotension and electrolyte disturbances.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to increased risk of hypotension.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not FDA-approved for pediatric use; limited data: 0.2 mcg/kg/min IV infusion, titrated to effect; max 0.8 mcg/kg/min.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at low end of dosing range (0.1 mcg/kg/min) due to increased sensitivity to hypotension; monitor blood pressure closely.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
No FDA black box warning.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Hypotension risk: Monitor blood pressure closely; may cause excessive hypotension.,Tachycardia: Can increase heart rate; caution in patients with coronary ischemia or tachyarrhythmias.,Glaucoma risk: May increase intraocular pressure; avoid in patients with glaucoma.,Hypokalemia: Monitor potassium levels; may cause hypokalemia.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Known hypersensitivity to fenoldopam or any component,Patients with glaucoma
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
No specific food interactions reported. However, patients should avoid excessive caffeine or stimulants as they may affect blood pressure.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Risk in first trimester: No adequate human studies; animal studies show no teratogenic effects at clinically relevant doses. Risk in second and third trimesters: Potential for fetal hypotension and decreased uteroplacental perfusion; use only if clearly needed. Avoid in severe preeclampsia or eclampsia due to risk of significant maternal hypotension.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
No data on presence in human milk; M/P ratio unknown. Caution advised; consider benefits of breastfeeding vs potential risk of infant exposure.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No standard dose adjustments required; but use lowest effective dose due to increased sensitivity to hypotensive effects in pregnancy. Titrate carefully.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Fenoldopam is a dopamine D1-like receptor agonist used for severe hypertension and hypertensive emergencies. It causes rapid, titratable blood pressure reduction without the toxic metabolites seen with nitroprusside. It also increases renal blood flow and natriuresis, making it beneficial in patients with renal impairment. Avoid in patients with glaucoma (increases intraocular pressure) or sulfite allergy (contains sodium metabisulfite).
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
This medication is given intravenously and is only used in a hospital setting.,You will have your blood pressure and heart rate monitored continuously during the infusion.,Report any headache, flushing, or dizziness to your nurse.,Do not stop the infusion suddenly; the dose will be gradually decreased.,Avoid consuming caffeine or other stimulants during treatment.,Tell your healthcare provider if you have glaucoma or a history of sulfite allergy.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
"Fenoldopam, a dopamine D1-like receptor agonist used for in-hospital blood pressure reduction, can potentiate the hypotensive and hypovolemic effects of the loop diuretic ethacrynic acid. Ethacrynic acid induces sodium and water diuresis, leading to reduced intravascular volume; Fenoldopam causes arterial vasodilation. When co-administered, the combined hemodynamic stress may increase the risk of excessive hypotension, renal hypoperfusion, and acute kidney injury, particularly in patients with compromised cardiac output or volume depletion."
"Iloprost, a prostacyclin analog, enhances vasodilation and inhibits platelet aggregation via IP receptor activation, increasing intracellular cAMP. Fenoldopam, a selective dopamine D1 receptor agonist, induces systemic and renal vasodilation through cAMP-dependent pathways. Concomitant use amplifies the hypotensive effect, potentially leading to severe hypotension, reflex tachycardia, and end-organ hypoperfusion, especially in patients with compromised cardiovascular reserve."
"Amlodipine, a dihydropyridine calcium channel blocker, reduces peripheral vascular resistance by inhibiting calcium influx into vascular smooth muscle cells. Fenoldopam, a selective dopamine D1 receptor agonist, causes arterial vasodilation, particularly in the renal and mesenteric beds. The concurrent use of these two vasodilatory agents leads to additive hypotension, potentially causing symptomatic drops in blood pressure, dizziness, and syncope, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENOLDOPAM MESYLATE vs ALDOCLOR-250, answered by our medical review team.
FENOLDOPAM MESYLATE is a Antihypertensive that works by Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENOLDOPAM MESYLATE and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENOLDOPAM MESYLATE is: 0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENOLDOPAM MESYLATE and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENOLDOPAM MESYLATE is classified as Category C. Risk in first trimester: No adequate human studies; animal studies show no teratogenic effects at clinically relevant doses. Risk in second and third trimesters: Potential for feta. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.